129. Chronic Kidney Disease, Cholesterol LDL, Urinary Antigen Testing, Gout, Pharmaceutical Industry,

https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2762699Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration RateThe answer was no; In a 5-year follow-up, ACE-I/ARB discontinuation was associated with an increased risk of both mortality (hazard ratio, 1.39; 95% CI, 1.20-1.60) and major adverse cardiovascular events (hazard ratio, 1.37; 95% CI, 1.20-1.56).https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2762509Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018pharma makes a lot of money—how do they spend ithttps://www.ncbi.nlm.nih.gov/pubmed/31801739With the best way to treat gout according to his article in annals rheumatology disease titled the contact trial-“comparing naproxen and low-dose colchicine for treatment of gout flares in primary care ““electric scooter injuries and hospital admissions in the United States, 2014-2018” - https://www.ncbi.nlm.nih.gov/pubmed/31913417“What is the risk of missing legionaires disease relying on urinary antigen testing solely? A retrospective Belgian multicenter study.“https://www.ncbi.nlm.nih.gov/pubmed/31838606The association between low-density lipoprotein cholesterol and incident atherosclerotic cardiovascular disease in older adults: Results from the National Institutes of Health pooled cohorts.” Which looked at the degree between ldl cholesterol levels and risk of first cardiovascular event in 2700 healhty adults age >75yrs old. And in the end both unadjusted and adjusted analyses, researchers found no significant association between LDL cholesterol levels and 5-year incidence of adverse CV events